This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.
Pharmacokinetic;Safety
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Administered by subcutaneous injection
Administered by subcutaneous injection
The Sceond Affiliated Hospital of Nanchang University
Nanchang, China
Evaluate the PK parameters of IBI362 in healthy Chinese male subjects
Peak Plasma Concentration (Cmax)
Time frame: From the first dose of study drug until 8 weeks
Evaluate the PK parameters of IBI362 in healthy Chinese male subjects
Area under the plasma concentration versus time curve (AUC)
Time frame: From the first dose of study drug until 8 weeks
Number of Participants With Adverse Events
The relationship of each adverse event to the investigational product was assessed by the investigator.
Time frame: From the first dose of study drug until 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.